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Osteoporosis
C. Conrad Johnston, Jr, MD*

fd. Note - This overview was originally presented at the
International Symposium on Clinical Disorders of Bone
and Mineral Metabolism, May 9-13,1983. The following
list indicates the presentations given in this session at the
Symposium and the contents ofthe corresponding
chapter in the Proceedings of the Symposium published by
Excerpta Medica. The numbers in parentheses refer to
pages in this volume. Complete information about the
contents of the Proceedings can be found at the back of
this issue.

Pathogenesis
O s t e o p o r o s i s is the most c o m m o n of the metabolic
bone diseases. A number of papers presented at this
symposium have indicated the progress made in this
field, relating both to the pathogenesis of the disease
and to its prevention and treatment.
N o r d i n , et al (pp. 323 ff.) reported additional data to
support their model for the determination of bone
volume by an independent variable (bone formation
rate) and a volume-dependent variable (fractional bone
resorption). In this case, mean-seam width was used as
an index of formation in biopsies from a group of premenopausal w o m e n in a state of equilibrium, when formation and resorption are balanced. Again, previously
reported correlations were f o u n d . Nordin feels that agerelated bone loss is associated with an increase in resorpt i o n , which is more marked in those w h o develop osteoporosis. The principal disagreement here is with the
methods used to estimate rates of resorption and bone
formation—measurement of resorption and formation
surfaces. Many investigators feel that rates cannot be
derived from staticsurface measurements. Nordin emphasizes the importance of the model or formation as an
independent variable, and believes that substitution of
other measures (i.e., the calcification rate derived from
tetracycline labeling) would only shift the curve and
would not alter the fundamental concept. Clearly, additional data using multiple methods to correlate change
over time will be needed to resolve this dilemma.

The determinants of bone volume in young adults. J.
Aaron, K. Sagreiya, D. Carter, and B.E.C. Nordin (323)
Microstructural and cellular basis of age-related bone
loss and osteoporosis. A . M . Parfitt, C.H.E. Mathews, A.R.
Vilanueva, D.S. Rao, M . Rogers, M . Kleerekoper, and B.
Frame (328)
Determinants of age-related bone loss. R.P. Heaney (333)
Heterogeneity of involutional osteoporosis: Evidence
for two distinct osteoporosis syndromes. B.L. Riggs, L.J.
M e l t o n III, and H.W. Wahner (337)
Steroid-induced osteoporosis. L.V. Avioli (343)
Can estrogen therapy prevent bone loss? R. Lindsay (346)
A m o d e l for establishing optimal prophylaxis and treatment in postmenopausal osteoporosis. C. Christiansen,
P. Rodbro, and L. Tjellesen (349)
Anabolic steroids and calcitonin in the treatment of
postmenopausal osteoporosis. C H . Chesnut 111, D.J. Baylink, H.E. Gruber, J. Ivey, M . Matthews, W.B. Neip, and
K. Sisom (355)

Parfitt, et al (p. 328 ff.) addressed the important problem
of age-related loss of trabecular bone f r o m a new perspective. Is this loss of trabecular b o n e d u e t o a decrease
in the number (density) of tra beeu lae or to a decrease in
the thickness of individual trabeculae? His studies indi-

Treatment of idiopathic osteoporosis with sodium fluoride. P.J. Meunier, K. Galus, D. Briancon, C. Edouard,
and S.A. Charhon (360)
The use of calcitrol (1,25 dihydroxyvitamin D) in osteoporosis. J.C. Gallagher (364)
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Osteopenia: TheADFR treatment. H.M. Frost (368)
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cate that both mechanisms are in part responsible, but
loss of trabeculae is the predominant mechanism, both
for age-related loss and for the more marked deficit
f o u n d among osteoporotics. A reduction in the meanwall thickness of individual structural units can explain
the thinness o f i n d i v l d u a l trabeculae but not total lossof
the structure. He suggests that during the accelerated
phase of bone loss, shortly after menopause, osteoclasts
perforate trabeculae; thus, there is no remaining structure upon which new bone can be rebuilt. A similar
mechanism may be responsible for endosteal bone loss.

balance; 3) remodeling rate; and 4) time. Many factors
may affect the first three variables to produce the bone
mass found at any time.
Mechanical loading, perhaps through direct or indirect
stimulation of osteoblasts (thereby producing a positive
remodeling balance) may be important, both in attainment of peak adult bone mass and in subsequent rates of
loss. With age, there is a reduction of peak strains
induced, rate of strain, and diversity of activity performed. These factors may lead to a negative remodeling
balance and bone loss.

Studies utilizing tetracycline labeling as a measure of
bone apposition indicate that osteoblast function declines
with age in normal individuals and, to a more marked
degree, in osteoporotics. After menopause, the increase
in bone remodeling persists for some time. Among some
who will develop osteoporosis, the rapid remodeling
ceases for unknown reasons, and this cessation may be an
important factor in fracture pathogenesis. He suggests
that some osteoporotics start with low bone mass at
maturity and have a prolonged phase of accelerated bone
loss, the result of which is low bone mass and fracture.
These individuals would have high remodeling on biopsies taken at the time of fracture. Others have rapid loss
but are unable to compensate, and decreased remodeling is found on biopsy. Thus, the heterogeneity of morphometric variables in osteoporosis can be explained.
Parfitt presented a new hypothesis which places great
emphasis on loss of structural elements due to increased
osteoclast activity. Because this phenomenon occurs
years before fracture, prevention and treatment must
focus on the years associated with rapid bone loss,
shortly after the menopause. Nordin stressed increased
resorption as the primary event responsible for bone loss
in osteoporosis. Measured variables are derived from
static measurement of bone surfaces at the time of fracture. Parfitt emphasized that most o f t h e bone loss is due
to removal of structural elements during the rapid phase
of bone loss after the menopause, and this loss is due to
osteoclast penetration of existing trabeculae. Could the
increased resorption surfaces seen by Nordin reflect the
previous activity postulated by Parfitt? Clearly, additional studies are necessary, but the focus of research
should shift from the patient with the disease (fracture)
to the individual w h o loses bone at a rapid rate some
years before the morbid event.
Low bone mass is one of the principal determinants of
osteoporotic fractures. Heaney, et al (pp. 333 ff.) reviewed
the complex mechanisms responsible for determination
of bone mass in the aging individual. Four elements are
important: 1) peak bone mass achieved; 2) remodeling
224

Remodeling rates may be determined primarily by parathyroid hormone secretion. In the presence of a negative remodeling balance, such as is f o u n d in aging
individuals, an increase in remodeling rate w o u l d lead to
more rapid loss of bone. Increased effective calcium
intake will suppress parathyroid hormone (PTH) and,
thus, remodeling. It is not entirely clear whether calcium
intake within the usually-expected range affects bone
loss, but inadequate intake certainly could accelerate
loss caused by other factors. Other nutrients may negatively affect calcium balance as well, especially excessive
intakes of protein and alcohol.
Estrogen deficiency is associated with accelerated bone
loss, although the mechanisms are not clear. Remodeling rates are increased by estrogen withdrawal, and in
the presence of a negative remodeling balance, more
rapid loss w o u l d ensue. Estrogen also appears to affect
calcium homeostatic mechanisms, which lead to more
effective absorption from gut, renal calcium conservation, and a blunted PTH effect.
Calcitonin may play a role in age-related bone loss, but
this role remains to be clearly delineated; also, accumulation of structural errors,such as perforation of trabeculae by excessive osteoclastic resorption (as suggested by
Parfitt), may be important.
Clearly, many factors are important in the determination
of bone mass, and it is only through a better understanding of these mechanisms that a rational approach to
prevention of bone loss can be derived.
It has generally been assumed that osteoporotic fractures
of the vertebrae, distal radius, and hip have a similar
pathogenesis. However, Riggs, et al (pp. 337 ff.) suggested
that there are several osteoporotic syndromes. Type 1
osteoporosis is associated with excessive trabecular bone
loss and leads to vertebral collapse fractures and to Colles
fractures, especially among women 50 to 65 years of age.
It is postulated that estrogen deficiency leads to an
increased bone sensitivity to the action of PTH, and that
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this activity causes loss of bone. The calcium mobilized
with bone loss reduces PTH secretion but not enough to
prevent excessive bone loss. However, since serum PTH
concentration is reduced, less 1,25(OH)2D3is synthesized
by the kidney, and calcium malabsorption ensues. Since
all w o m e n are estrogen-deficient after menopause, and
no measured difference in sex hormone concentrations
has been found between the majority w h o do not
develop osteoporosis and the small group w h o do, Riggs
postulated that there is some undefined intrinsic abnormality of bone which predisposes to excessive loss with
estrogen deficiency. Nordin has suggested that the osteoporotics have more marked calcium malabsorption, which
should lead to increased secretion of PTH, and Riggs has
f o u n d PTH concentrations to be low in this group, c o m pared to controls. Thus, the predisposing factors remain
to be determined.

being less deleterious to mineral homeostatis than currently available drugs.

Prevention and Treatment
The treatment of osteoporosis must be considered from
the standpoint of both prevention of bone loss and therapy of the patient after fracture has occurred. Lindsay
(pp. 346 ff.) reviewed the evidencethat administration of
estrogen can prevent loss of bone in postmenopausal
w o m e n . This effect has been demonstrated, using techniques which measure both cortical and trabecular bone.
With therapy, bone loss can be prevented up to eight
years, when slow loss may begin. When estrogen is withdrawn, loss ensues, but it is no greater than the loss
occurring after natural menopause. Administration of
estrogen is also associated with less loss of height and
fewer vertebral deformities than occur in placebo-treated
controls. Christiansen, et al (pp. 349 ff.) also noted that a
combination of estrogen and progesterone prevents cortical bone loss. The principal problem of prophylaxis with
estrogen is the determination of w h o should receive the
drug, since it can be toxic. Christiansen has found that
there is a population of rapid bone losers that, he predicts, will develop osteoporosis. There women have
lower estrogen concentrations, higher serum alkaline
phosphatase, and higher urinary h y d r o x y p r o l i n e /
creatinine ratios than those who lose bone more slowly.
While this problem requires additional study, these data
provide promising leads to the development of a simple
screening procedure to select women for prophylactic
estrogen therapy shortly after the onset of menopause.

Type 2 osteoporosis is associated with the loss of both
trabecular and cortical bone, and eventually leads to hip
and vertebral fractures. It occurs primarily in individuals
over 75; although more c o m m o n in w o m e n , it also
affects men. It is postulated that a primary defect in
1,25(OH)2D3 synthesis leads to calcium malabsorption
and secondary hyperparathyroidism with increased bone
turnover. Since there is a negative remodeling balance at
individual sites, bone loss occurs.
Riggs, his associates, and others have accumulated evidence that the different fracture syndromes generally
associated with osteoporosis may be due to different
mechanisms of bone loss. This concept is important in
designing effective programs for prophylaxis and treatment. Clearly, we would not wish to introduce a therapeutic program to prevent one fracture type that would lead
to a greater risk of developing another fracture syndrome.

Chesnut and associates (pp. 355 ff.) demonstrated that
administration of calcitonin to patients with osteoporotic fractures led to an increase in total body calcium, as
measured by neutron activation. This increase persisted
for 18 months, but by 26 months the rate of gain was not
sustained; no change in regional bone mass could be
measured by photon absorptiometry. The patients tolerated the calcitonin well with few adverse reactions. This
group has also demonstrated that administration of stanozolol to a similar population of postmenopausal
osteoporotic patients was associated with a significant
increase in total body calcium at 26 months on therapy.
The magnitude of the increase in calcium retention
seemed to persist throughout the study. Analysis of biochemical and histologic data suggested that the effect of
the drug was to stimulate bone formation. Transient
elevations in SCOT were noted in some patients, as well
as some evidence of increased facial hair, ankle edema,
and hoarseness. Neitherstudy contained sufficient n u m bers of patients to determine whether the incidence of
fractures was reduced.

The important clinical problem of steroid-induced osteoporosis was reviewed by Avioli (pp. 343 ff.). Glucocorticoids seem to produce loss of trabecular bone primarily
and, thus, vertebral fractures. The effect is dose and time
dependent, but it can occur with as little as 7 mg of
prednisone a day or its equivalent. Those particularly at
risk are growing children, postmenopausal w o m e n , and
those receiving other drugs which may affect the skeleton, such as anti-convulsants. Glucocorticoids have multiple effects that are responsible for bone loss, including
impaired calcium absorption, increased calcium excretion by the kidney, and impaired osteoblast function.
No effective means is currently available to prevent
these complications, other than reduction in dose and
time of administration when possible. A new glucocorticoid under development, Deflazacort, shows promise of
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Meunier, et al (pp. 360 ff.) presented data on 57 osteoporotic patients treated for two years with a combination of
sodium fluoride, calcium, and vitamin D. No control
group was included. Fifty-six percent of the patients
experienced relief from back pain after two years of
therapy. The incidence of vertebral fracture was lower in
the second year of treatment than in the first, and the
mean annual increase in the radiological vertebral index
was also lower during the second year. No significant
changes were found in the biochemical parameters
measured. Bone biopsies were performed before and
after treatment i n i l patients classified as good responders; there was a marked increase in the osteoid surfaces
and osteoblastic surfaces without an increase in the
resorption surfaces. The increase in trabecular bone
volume was also marked in these biopsies. The newlyformed bone was lamellar in character. No microradiographs were performed, but some evidence in the literature suggests that newly-formed bone is not as well
calcified as normal bone. Side effects consisted of mild
gastrointestinal irritation in 22% o f t h e patients and transient periarticular pain in 33%, but only 7% o f t h e patients
discontinued therapy because of adverse reactions. Some
patients treated with fluoride did not appear to respond
to the therapy. Meunier found that some showed no
response on formation surfaces, while others had increased
formation surfaces but did not gain bone. The mechanisms for these changes remain to be elucidated.
Initial studies have been undertaken to evaluate the
effect of 1,25(OH)2D3. When this drug was given in a
preliminary study, bone volume increased significantly
at 24 months, as measured on iliac crest biopsies. The
calcium balance improved so that it was positive after six
months, but subsequently a less positive balance was
f o u n d . There appeared to be a significant decrease in
vertebral fractures in the treated group. Additional
studies will be necessary to evaluate this therapeutic
agent in the treatment of osteoporosis.

A new approach to the treatment of osteoporosis, the
" A D F R " m e t h o d , has been developed. Currently under
evaluation, this method was reviewed by Frost (pp. 368
ff.). An agent k n o w n to activate bone remodeling is
adminstered in pulsatile fashion in order to activate a
number o f t h e bone remodeling units simultaneously. A
medication which will depress osteoclastic activity during the resorptive phase is then administered, thus
reducing the amount of bone removed. Subsequently, a
free period is allowed so that the osteoblasts will replace
their programmed quantum of bone. Since the osteoclasts have removed less bone, bone balance will be
positive. The entire sequence can then be repeated. This
method was developed based on the current understanding of bone function as an organ. Preliminary data
from animal studies appear to indicate that the sequence
will produce its desired effect.
Progress has been made over the past decade in our
understanding of osteoporosis. Use o f t h e bone biopsy
has led to a better understanding of the pathogenesis of
age-related bone loss, although controversy still remains.
Efforts should be focused on that period of rapid bone
loss that occurs shortly after menopause. Many factors
may be important in the development of maximum adult
bone mass and its subsequent rate of loss, including
mechanical loading, hormonal influences, and nutrition
factors. These all provide fertile areas for additional
research during the next few years. Since the fracture
syndromes generally associated with osteoporosis may
be due to different pathogenic mechanisms, an approach
to prevention and treatment may require awareness of
this heterogeneity. The application of the ADFR theory
may allow even further advances. As progress is made to
identify patients w h o will subsequently be at risk of fracture, a rational prophylaxis can be designed. The next
decade should provide exciting new insights into the
pathogenesis and treatment of osteoporosis.
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